Copy Number Variation Detection for the Indication of Targeted Therapy in a Lung Cancer Patients Series. Next-Generation Sequencing Panel vs Fluorescent in-Situ Hibridization.
Natalia Rodon1, Marta Salido1,2, Yessica No Garbarino1, Olga Diaz1 , Marta Ferrer3, Estefania García3, Enric Carcereny3, Eugeni Saigi3 and Xavier Puig1,4,5.
1BIOPAT. Biopatologia Molecular SL. Grup Assistència. Barcelona, Spain. 2Laboratorio de Citogenética Molecular. Servicio de Patologia. Hospital del Mar. Barcelona. Spain 3Servicio de Oncologia. SCIAS-Hospital de Barcelona, Grup Assistència. Barcelona, Spain. 4HISTOPAT SL. Barcelona, Spain. 5SCIAS-Hospital de Barcelona, Grup Assistència. Barcelona, Spain.
Background
Copy Number Variation Detection for the Indication of Targeted Therapy in a Lung Cancer Patients Series. Next-Generation Sequencing Panel vs […]